Related Experiment Video
Updated: Jun 14, 2025
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
[Rituximab based treatment in pediatric Epsstain Bar Virus associated lymphocyte proliferative diseases after
Insights
Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorders (PTLD) are a severe complication after hematopoietic stem cell transplantation (HSCT). This study found no significant difference in survival rates between rituximab monotherapy and combination therapy for PTLD in aplastic anemia patients.
Area of Science:
- Hematology
- Oncology
- Infectious Diseases
Background:
- Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorders (PTLD) represent a critical complication following hematopoietic stem cell transplantation (HSCT).
- Aplastic anemia (AA) patients undergoing haploidentical transplantation are susceptible to PTLD, necessitating investigation into clinical characteristics and treatment outcomes.
Purpose of the Study:
- To summarize the clinical characteristics of 31 aplastic anemia patients who developed PTLD after haploidentical HSCT.
- To compare the efficacy of rituximab monotherapy versus combination therapy in managing PTLD.
- To identify risk factors influencing PTLD prognosis after HSCT.
Main Methods:
- Retrospective analysis of 31 aplastic anemia patients with PTLD post-haploidentical HSCT.
- Classification of patients into rituximab monotherapy or combination therapy groups based on treatment response.
- Statistical analysis to compare treatment outcomes and identify prognostic factors.
Main Results:
- The incidence of PTLD in children with AA after HSCT was 10.16%.
- Patients over 10 years old had a significantly increased incidence of PTLD (P=0.010).
- The 2-year overall survival rate was 89.7±5.6%, with three deaths. Standard pre-treatment protocols and EBV reactivation were identified as risk factors. No significant difference in prognosis was observed between the two treatment groups.
Conclusions:
- EBV-PTLD in AA patients post-HSCT has a significant impact on survival.
- Age >10 years is a risk factor for developing PTLD after HSCT in AA patients.
- Rituximab monotherapy and combination therapy showed similar prognostic impact, suggesting further research into optimal treatment strategies.
Abstract:
Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorders (PTLD) are one of the most severe complications after hematopoietic stem cell transplantation (HSCT). This study includes 31 cases of aplastic anemia (AA) patients who developed PTLD after haploidentical transplantation, summarizing their clinical characteristics and categorizing them into either rituximab monotherapy group or combination therapy group based on whether their condition improved by 1 log after a single dose of rituximab. The incidence of PTLD after HSCT in children with AA was 10.16%, and the incidence of PTLD in patients with age >10 years was significantly increased (χ(2)=11.336, P=0.010). Of the 31 patients, 27 were clinically diagnosed and 4 were pathologically confirmed. Finally, 15 patients were classified into the rituximab treatment group and 15 patients into the combination treatment groups. Finally three patients died, and the 2-year overall survival rate was (89.7±5.6) %. Standard pre-treatment protocols and EBV reactivation are risk factors affecting the prognosis of PTLD. There was no statistically significant difference in the impact of the two treatment schemes on prognosis.
